Browsing by Author "Briassoulis, E. Ch"
Now showing items 21-40 of 77
-
Article
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma
Tsavaris, N.; Mylonakis, N.; Karvounis, N.; Bacoyiannis, Charalambos; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Stamatelos, G.; Kosmidis, Paraskevas A. (1994)From June 1985 to March 1993, 20 consecutive patients with histologically proven malignant mesothelioma were treated with cisplatin 100 mg/m2 i.v. infusion on day 1 and vinblastine 6 mg/m2 i.v. on day 1 and 8. Treatment ...
-
Article
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study
Briassoulis, E. Ch; Tsavaris, N.; Fountzilas, George; Athanasiades, A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Samantas, E.; Pavlidis, Nicholas (1998)The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...
-
Article
Diagnostic and therapeutic management of cancer of an unknown primary
Pavlidis, Nicholas; Briassoulis, E. Ch; Hainsworth, J.; Greco, F. A. (2003)Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man. Patients with CUP present with metastatic disease ...
-
Article
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study
Pentheroudakis, George; Briassoulis, E. Ch; Kalofonos, H. P.; Fountzilas, George; Economopoulos, T.; Samelis, G.; Koutras, A. K.; Karina, M.; Xiros, N.; Samantas, E.; Bamias, A. T.; Pavlidis, Nicholas (2008)Introduction. Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer
Razi, E. D.; Dimopoulos, M. A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Briassoulis, E. Ch; Samantas, E.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Fountzilas, George (2001)The purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group
Fountzilas, George; Papadimitriou, C.; Dafni, U.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Moulopoulos, L. A.; Razi, E. D.; Kalofonos, H. P.; Aravantinos, Gerasimos; Briassoulis, E. Ch; Papakostas, P.; Abela, K.; Gogas, H.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, ...
-
Article
Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer
Briassoulis, E. Ch; Pappas, P.; Puozzo, C.; Ch, F. Tolis; Fountzilas, George; Dafni, U.; Marselos, M.; Pavlidis, Nicholas (2009)Aim: To determine the safe dose range and pharmacokinetics of metronomic oral vinorelbine and obtain preliminary data on biomarkers and efficacy in patients with advanced cancer. Methods: Successive cohorts ofpatients ...
-
Article
Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG)
Pectasides, Dimitrios; Papaxoinis, G.; Fountzilas, George; Aravantinos, Gerasimos; Bamias, A. T.; Pavlidis, Nicholas; Kalofonos, H. P.; Timotheadou, E.; Samantas, E.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Economopoulos, T.; Dimopoulos, M. A. (2009)Background: The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC). Patients and Methods: ...
-
Article
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)
Briassoulis, E. Ch; Ch, F. Tolis; Bergh, Jonas; Pavlidis, Nicholas (2005)
-
Article
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)
Briassoulis, E. Ch; Ch, F. Tolis; Pavlidis, Nicholas (2001)
-
Article
Evaluation of six tumor markers in patients with carcinoma of unknown primary
Pavlidis, Nicholas; Kalef-Ezra, J. A.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Saferiadis, K.; Bairaktari, Eleni Th; Bafaloukos, Dimitrios; Maravegias, A.; Theoharis, D.; Fountzilas, George (1994)We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
-
Article
Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction
Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, Nicholas (2006)The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver ...
-
Article
Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer. A randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Zisiadis, A.; Dafni, U.; Konstantaras, C.; Hatzitheoharis, G.; Papavramidis, S.; Bousoulegas, A.; Basdanis, G.; Giannoulis, E.; Dokmetzioglou, J.; Katsohis, C.; Nenopoulou, E.; Karvounis, N.; Briassoulis, E. Ch; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (2000)Background: It has been shown in randomized studies that adjuvant treatment with the combination of fluorouracil (FU) and levamisole reduced the risk of recurrence and deaths of patients with stage III colon cancer. ...
-
Article
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial
Kosmidis, Paraskevas A.; Tsavaris, N.; Skarlos, Dimosthenis V.; Theocharis, D.; Samantas, E.; Pavlidis, Nicholas; Briassoulis, E. Ch; Fountzilas, George (1996)Purpose: To investigate if double modulation of fluorouracil (5-FU) with leucovorin (folinic acid [FA]) and interferon alfa-2b (IFN 2b) improves responses and survival in comparison to single modulation of 5-FU with FA. ...
-
Article
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting
Briassoulis, E. Ch; Andreopoulou, E.; Ch, F. Tolis; Bairaktari, Eleni Th; Katsaraki, A.; Dimopoulos, M. A.; Fountzilas, George; Seferiadis, C.; Pavlidis, Nicholas (2001)BACKGROUND. Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS. ...
-
Article
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group
Briassoulis, E. Ch; Pavlidis, Nicholas; Terret, C.; Bauer, J.; Fiedler, W.; Schöffski, P.; Raoul, J. L.; Hess, D.; Selvais, R.; Lacombe, D.; Bachmann, P.; Fumoleau, P. (2003)The activity of glufosfamide (β-D-glucopyranosyl-N,N′ -di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-naïve patients with ...
-
Article
Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression
Ioachim, E.; Charchanti, A.; Briassoulis, E. Ch; Karavasilis, V.; Tsanou, E.; Arvanitis, D. L.; Agnantis, Niki J.; Pavlidis, Nicholas (2002)The immunohistochemical expression of the extracellular matrix (ECM) components tenascin (TN), fibronectin (FN), collagen type IV (Coll) and laminin (LN), and their possible relationships were studied in a series of 134 ...
-
Article
Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma
Tsanou, E.; Ioachim, E.; Briassoulis, E. Ch; Damala, K.; Charchanti, A.; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2004)The most important cellular protective mechanisms against oxidative stress are antioxidant enzymes. Their action is based on decomposal of reactive oxygen species (ROS) and their transformation to H2O2. Within the mitochondria ...
-
Article
Interaction pharmacokinetis of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Soulti, K.; Piperidou, C.; Pavlidis, Nicholas (2004)Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. Methods: ...
-
Article
Is interferon-a an active agent in Castleman's disease?
Pavlidis, Nicholas; Briassoulis, E. Ch; Klouvas, G. D.; Bai, M. C. (1992)